Drug Trial Radar · NCT00385138
Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.
Last checked: Nov 20, 2026Latest source record: May 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5,364
Actual
Start
Sep 2006
Primary completion
May 2009
Study completion Jun 2010
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to demonstrate that the efficacy of cangrelor (combined with usual care) is superior to that of usual care, in subjects requiring percutaneous coronary intervention (PCI) as measured by a composite of all-cause mortality, myocardial infarction (MI), and ischemia-driven revascularization (IDR).
Conditions
- Atherosclerosis
- Acute Coronary Syndrome (ACS)
Interventions
CangrelorDrug
cangrelor bolus (30 mcg/kg) \& cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
clopidogrelDrug
clopidogrel capsules (600 mg) at end of PCI
Placebo bolus & placebo infusionDrug
placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Placebo capsules - end of PCIDrug
Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
Placebo capsules - end of infusionDrug
Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of All-cause Mortality, Myocardial Infarction (MI), and Ischemia-driven Revascularization (IDR)Time frame: randomization through 48 hours post randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Innovis Health
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.